Skip to content
EN
info@priavoid.com
+49 211 942 522 98
Toggle Navigation
About us
Platform
Pipeline
Partnering
Media
Contact
Philipp.Buerling
News, Press Release
PRImus-AD: Recruitment for Phase II clinical trial of Alzheimer’s drug PRI-002 successfully completed
Read more
News, Press Release
Priavoid receives funding from the Alzheimer’s Association and the Rainwater Charitable Foundation to further develop its tau program
Read more
News, Press Release
New Alzheimer’s drug PRI-002 receives EMA approval for Phase II study
Read more
News
Priavoid selected to German Accelerator Program
Read more
News, Press Release
Priavoid and Research Center Jülich receive funding from The Michael J. Fox Foundation
Read more
News, Press Release
Priavoid closes financing round
Read more
News, Press Release
Alzheimer´s Research: Important Milestone for PRI-002
Read more
News
Priavoid Headquarters at Life Science Center Düsseldorf
Read more
News, Press Release
Nobel Prize winner Stanley Prusiner joins Priavoid’s supervisory board
Read more
News
Philipp Bürling appointed CEO of Priavoid
Read more
Page load link